财务数据关键指标变化 - 公司2025年第二季度净亏损为3716万美元，较2024年同期的4052万美元有所减少[18] - 公司2025年第二季度每股亏损为0.44美元，较2024年同期的0.48美元有所改善[18] - 公司现金及现金等价物和有价证券从2024年12月31日的4.547亿美元降至2025年6月30日的3.797亿美元[12] 成本和费用 - 研发费用从2024年第二季度的3470万美元降至2025年第二季度的3230万美元，减少了240万美元[13] - 一般及行政费用从2024年第二季度的1220万美元降至2025年第二季度的910万美元，减少了320万美元[14] 业务线表现 - 公司HCV Phase 2研究结果显示，治疗依从性人群的SVR12（持续病毒学应答）率为98%（210/215）[9] - 公司HCV Phase 3临床试验计划招募约880名初治患者，包括有和无代偿性肝硬化的患者[7] - 公司依赖其最先进的产品候选药物，特别是用于治疗HCV的bemnifosbuvir/ruzasvir方案[25] 市场与行业数据 - 全球HCV患者数量估计为5000万人，每年新增约100万例感染[5][22] - 美国慢性HCV患者数量在240万至400万人之间[5][22] 公司战略与风险 - 公司正在评估战略替代方案，但完成时间未知且结果不确定[25] - 公司提到在2025年3月31日结束的季度报告中讨论了重要风险因素[25] 资本运作 - 公司已回购4,619,597股普通股，平均购买价格为每股3.01美元，总金额约为2500万美元[14]

收入和利润（同比环比） - 公司第二季度GAAP收入为1.03亿美元，同比增长138%，环比增长3%[6] - 2025年第二季度总收入为1.02952亿美元，同比增长138%[20] - 公司GAAP净亏损910万美元，较去年同期的2610万美元亏损收窄65%[6] - 非GAAP净亏损880万美元，较去年同期的1090万美元亏损收窄19%[6] - 2025年第二季度非GAAP净亏损为883万美元，较2024年同期的1085.6万美元改善19%[22] - 2025年第二季度每股GAAP净亏损为0.16美元，较2024年同期的0.66美元改善76%[20] - 2025年第二季度非GAAP每股净亏损为0.16美元，较2024年同期的0.28美元改善43%[22] 成本和费用（同比环比） - 第二季度GAAP毛利率为30.3%，同比提升8.2个百分点，环比下降0.3个百分点[6] - 2025年第二季度总毛利率为31.162百万美元，较2024年同期的9.562百万美元增长226%[20] - 2025年上半年总研发支出为3842.2万美元，较2024年同期的2479万美元增长55%[20] 各条业务线表现 - 数据中心业务稳步增长，CATV业务需求保持强劲[3] - CATV业务收入从2024年第二季度的581.8万美元增长至2025年第二季度的5601.9万美元，增幅达863%[20] - 数据中心业务收入从2024年第二季度的3435.2万美元增长至2025年第二季度的4479.1万美元，增长30%[20] 管理层讨论和指引 - 公司预计第三季度收入在1.15亿至1.27亿美元之间，非GAAP毛利率在29.5%至31.0%之间[10] - 预计到2025年底将实现每月10万只800G收发器的产能，其中40%在美国生产[3] - 台湾工厂已获主要超大规模客户批准生产800G产品[3] 其他财务数据 - 截至2025年6月30日，公司现金及现金等价物为8719.5万美元，较2024年底增长10%[18] - 应收账款净额为2.11452亿美元，较2024年底增长81%[18] - 2025年第二季度运营亏损为1597.6万美元，较2024年同期的2624.4万美元改善39%[20] - 2025年第二季度调整后EBITDA为-341.8万美元，较2024年同期的-1192万美元改善71%[22]

RELEASE $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT South San Francisco, Calif., August 7, 2025 -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported second quarter 2025 financial results and recent portfolio and business updates. As of ...

Funko Reports Second Quarter 2025 Financial Results --Company Provides Comments on H2 Outlook-- EVERETT, Wash. August 7, 2025 -- Funko, Inc. (Nasdaq: FNKO), a leading pop culture lifestyle brand, today reported its consolidated financial results for the second quarter ended June 30, 2025. Second Quarter Financial Results Summary: 2025 vs 2024 "As expected, our 2025 second quarter performance was impacted by a dynamic and uncertain tariff environment," said Mike Lunsford, Interim Chief Executive Officer of F ...

Exhibit 99.1 Rackspace Technology Reports Second Quarter 2025 Results SAN ANTONIO, August 7, 2025 – Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end, hybrid cloud and AI solutions company, today announced results for its second quarter ended June 30, 2025. Amar Maletira, Chief Executive Officer, stated, "I am pleased with our second quarter results. Revenue and operating profit exceeded the midpoint of guidance and EPS was within our guided range." Mr. Maletira added, "Go‑to‑market execution a ...

COMPANY CONTACTS Briony Quinn Chief Financial Officer (240) 744-1196 Dori Kesten Capital Markets (617) 835-8366 DIAMONDROCK HOSPITALITY COMPANY REPORTS SECOND QUARTER 2025 RESULTS "RevPAR in the second quarter was in line with our expectations, with demand down modestly and rates up compared to the same time last year. Out-of-room spend accelerated from levels experienced in the first quarter, and that trend has continued into the third quarter. Excluding a larger than anticipated property tax increase in C ...

Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 Cambridge, Mass. – August 7, 2025 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small mo ...

Westrock Coffee Company Reports Second Quarter 2025 Results and Reaffirms 2025 and 2026 Outlook Exhibit 99.1 Little Rock, Ark., August 7, 2025 (GLOBE NEWSWIRE) – Westrock Coffee Company (Nasdaq: WEST) ("Westrock Coffee" or the "Company") today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights 1 Commenting on our results, Scott T. Ford, CEO and Co-founder stated, "We are pleased to report record quarterly segment performance as we celebrate the successful launch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31565 Flagstar Financial, Inc. (Exact name of registrant as specified in its charter) | Delaware | | 06-1377322 | | --- | --- | --- | | (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-36393 Paycom Software, Inc. (Exact name of registrant as specified in its charter) Delaware FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or (State or other juri ...